Fortrea completes divestiture of Endpoint Clinical and Patient Access to Arsenal for $295M plus $45M milestone

Fortrea Holdings Inc.

Final purchase price $295M paid at closing plus $45M upon achieving transition milestones.
Net proceeds to be used to reduce a portion of Fortrea's overall debt.
Sam Osman appointed CEO of the new entities; Ray Hill named chairman.
Fortrea becomes a pure-play clinical CRO after the divestiture.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.